Health care still loves a divided Congress

Health care stocks skyrocketed after Tuesday’s election results indicated Republicans likely will maintain control of the Senate, all but assuring continued gridlock in both chambers of Congress. A Republican Senate means “the public option and direct government negotiation on drug prices are dead for at least the next two years,” Spencer Perlman, an analyst at…

Growth in Medicaid Enrollment and Spending

Analyzes Medicaid enrollment and spending trends for FY 2020 and FY 2021 based on data provided by state Medicaid directors as part of the 20th annual survey of Medicaid directors in all 50 states and the District of Columbia. Overall, 43 states2 responded to the survey by mid-August 2020, although response rates for specific questions varied.…

COVID-19 Impact on Outpatient Care: Visits Return to Pre-pandemic Levels, but Not for All Providers and Patients

Outpatient visits have returned to their pre-pandemic levels after declining by nearly 60%, according to a Commonwealth Fund new analysis. The huge drop in people seeking care was bad both for providers and for patients, many of whom delayed care for conditions that may have worsened. Telemedicine visits initially surged, but have since dropped off.…

The U.S. spends twice as much as comparable countries on health, driven mostly by higher payments to hospitals and physicians, NOT drugs!

Even though voters care a lot about drug prices, they’re NOT the main reason the U.S. spends so much on health care. The primary culprits are the twice as much per person spent on hospital and physician payments than comparable wealthy nations. And yet, according to a new Peterson-Kaiser Tracker analysis, the U.S. has worse health…